阿托伐他汀对糖耐量减低原发性高血压患者血管内皮功能的影响

目的探讨阿托伐他汀对糖耐量减低的原发性高血压(EH)患者血管内皮功能的影响。方法 EH合并糖耐量减低患者96例,随机分为对照组(常规治疗,50例),阿托伐他汀组(常规治疗+阿托伐他汀20mg/d,46例)。观察治疗前和治疗8周后血脂、血糖及血压变化,采用流式细胞术检测治疗前后外周血CD31+/AnnexinV+内皮微粒(EMPs)数量。结果治疗后,阿托伐他汀组外周血EMPs数量明显减少[(2342.5±856.2)个/ml vs.(1806.7±761.7)个/ml](P<0.01),对照组无明显变化[(2251.8±832.5)个/ml vs.(2152.5±815.1)个/ml](P>0.05)。治疗后,阿托伐他汀组甘油三酯(TG)、总胆固醇(TC)及低密度脂蛋白(LDL)水平明显低于对照组(P<0.05)。结论阿托伐他汀能显著降低EH合并糖耐量减低患者外周血EMPs数量,减轻内皮凋亡和损伤。

Effects of atorvastatin on vascular endothelial function in essential hypertensive patients with impaired glucose tolerance

Objective To investigate the effects of atorvastatin on vascular endothelial function in the patients with essential hypertensive(EH) and impaired glucose tolerance.Methods A total of 96 EH patients with impaired glucose tolerance was divided into two groups of A(50 cases,with conventional therapy) and B(46 cases,treated with additional atorvastatin 20 mg/d for 2 weeks).Plasma CD31+/Annexin V+ endothelial microparticles(EMPs) were measured by flow cytometry before and 8 weeks after treatment.The changes of blood lipids,glucose and BP were recorded as well.Results Plasma EMPs in group B were significantly lower after treatment than those before[(2342.5±856.2) pieces/ml vs.(1806.7±761.7) pieces/ml](P<0.01),which were not in group A[(2251.8±832.5) pieces/ml vs.(2152.5±815.1) pieces/ml](P>0.05).Plasma levels of TG,TC and LDL after treatment were lower in group B than those in group A(P<0.05).ConclusionAtorvastatin can decrease plasma EMPs,reduce the injury and apoptosis of endothelium in EH patients with impaired glucose tolerance.